Physician profile
Daniel E Verbist
NPI 1497194567
$875.09
in general payments reported to CMS, 2019-2025
14 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $80.94 · 2021: $245 · 2022: $47.43 · 2023: $14.10 · 2024: $26.37 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rti Surgical, INC | $168.41 | 2025 | |
| Mentor Worldwide LLC | $143.88 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Sientra, INC. | $112.09 | 2020-2021 | |
| Integra Lifesciences Corporation | $91.35 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $83.40 | 2019-2021 | |
| Depuy Synthes Sales INC. | $52.79 | 2021 | |
| Baxter Healthcare | $49.36 | 2019 | |
| Zimmer Biomet Holdings, INC. | $43.75 | 2019 | |
| Allergan, INC. | $42.55 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $27.83 | 2020 | |
| Kls-Martin L.P. | $16.92 | 2021 | |
| Elite Orthopedics, LLC | $15.12 | 2021 | |
| Bioventus LLC | $14.40 | 2022 | |
| Stryker Corporation | $13.24 | 2024 | Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Verbist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.